About Us

Fresenius Kabi at a glance

Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, we focus on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, we offer products for collection and processing of blood and cell components.

About us

Fresenius Kabi employs more than 37,000 people worldwide.

With our corporate philosophy of "caring for life", we are committed​ to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

In 2018, the company reported sales of more than €6.5 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.

Key Figures

€ in millions 2018 2017
Sales 6,544 6,358
EBITDA1 1,434 1,483
EBIT1 1,139 1,177
Net Income1,2 742 702
Employees (Dec 31) 37,843 36,380

1 Before special items
Net income attributable to shareholders of Fresenius SE & Co. KGaA